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SUMMARY
Members of the mammalian phosphoinositide-3-OH kinase (PI3K) family of proteins are critical regulators of
various cellular process including cell survival, growth, proliferation, and motility. Oncogenic activating muta-
tions in the p110a catalytic subunit of the heterodimeric p110/p85 PI3K enzyme are frequent in human
cancers. Here we show the presence of frequent mutations in p85a in colon cancer, a majority of which
occurs in the inter-Src homology-2 (iSH2) domain. These mutations uncouple and retain p85a’s p110-stabi-
lizing activity, while abrogating its p110-inhibitory activity. The p85amutants promote cell survival, AKT acti-
vation, anchorage-independent cell growth, and oncogenesis in a p110-dependent manner.INTRODUCTION
Phosphoinositide 3-kinase (PI3K) family of lipid kinases are
divided into three major classes based on primary sequence,
substrate preference, and regulation (Cantley, 2002; Engelman
et al., 2006; Fruman et al., 1998; Hawkins et al., 2006). While
class IA PI3Ks are heterodimeric enzymes composed of a cata-
lytic subunit (p110a, p110b, or p110d) complexedwith one of five
regulatory subunits (p85a, p55a, p50a, p85b, or p55g), the class
IB enzyme is a dimer made of p110g catalytic subunit and p101
or p84 regulatory subunit (Cantley, 2002; Hawkins et al., 2006;
Vanhaesebroeck et al., 2005). The class I catalytic subunit poly-
peptides p110a, p110b, p110d, and p110g are encoded by
PIK3CA, PIK3CB, PIK3CD, and PIK3CG, respectively (Cantley,
2002; Vanhaesebroeck and Waterfield, 1999). The regulatory
subunits are encoded by five genes: PIK3R1 codes p85a,Cp55a, and p50a; PIK3R2 codes p85b; PIK3R3 codes p55g;
PIK3R5 codes p101; and PIK3R6 codes p84 (Cantley, 2002;
Vanhaesebroeck and Waterfield, 1999).
The p110 catalytic subunits of PI3K share a common domain
architecture consisting of an N-terminal adaptor binding domain
that binds to p85 regulatory subunits, a Ras binding domain,
a putative membrane binding C2 domain, a helical region that
makes a regulatory contact with the p85 nSH2 domain (Miled
et al., 2007), and a C-terminal kinase domain. Similarly, the
p85 regulatory subunits have in common an N-terminal SH3
domain, a domain homologous to the Rho GTPase-activating
protein domain of the BCR gene product (BCR domain), and
twoSH2 domains (nSH2 and cSH2) that flank an intervening anti-
parallel coiled-coil (iSH2) required for binding to the adaptor
binding domain in p110 (Holt et al., 1994). Besides its role in
inhibiting the catalytic activity of p110, in the basal state, theSIGNIFICANCE
Somatic mutations in the catalytic p110a subunit of PI3K are common in cancers. In this study, we show the occurrence of
frequent mutations in the regulatory p85a subunit of PI3K in human cancers. Our data demonstrate an alternate mechanism
for PI3K pathway activation and oncogenesis resulting from the impaired regulation of p110 activity by mutant p85a.
Further, p85a mutations are likely to be useful as diagnostic markers for identification of p110-dependent tumors that
may not carry an activating p110a mutation, but are candidates for targeted treatment with PI3K pathway inhibitors that
are in development.ancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc. 463
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p85a Somatic Mutations Promote Tumorigenesisp85 regulatory subunit is required to stabilize the catalytic p110
subunit (Kodaki et al., 1994; Yu et al., 1998). Upon growth factor
stimulation, the nSH2 and cSH2 domains of p85 bind to phos-
phorylated tyrosines (YXXM motif) in activated receptors and
adaptors that activate catalytic p110 (Backer et al., 1992; Car-
penter et al., 1993; Otsu et al., 1991). Once activated, PI3Ks
phosphorylate phosphoinositide 4,5-bisphosphate leading to
the production of phosphoinositide 3,4,5-triphosphate, which
serves as an important second messenger that regulates cell
survival, growth, proliferation, and motility through a variety of
downstream effectors (Cantley, 2002; Carpenter et al., 1993;
Engelman et al., 2006; Jimenez et al., 2002; Vanhaesebroeck
and Waterfield, 1999; Yu et al., 1998).
Several studies have identified common somatic mutations in
PIK3CA in cancers of colon, rectum, breast, ovary, brain, and
liver (Bader et al., 2005; Samuels et al., 2004). Several PIK3CA
mutants, including hotspot mutations in the helical and kinase
domain, show elevated lipid kinase activity in vitro and induce
oncogenic transformation in vivo (Gymnopoulos et al., 2007; Ike-
noue et al., 2005; Isakoff et al., 2005; Kang et al., 2005; Samuels
et al., 2004; Zhao and Vogt, 2008).While oncogenic p110amuta-
tions are common in cancers (Bader et al., 2005; Samuels et al.,
2004), such mutations in the regulatory p85 subunit are not as
common (Bader et al., 2005; Hennessy et al., 2005). Previously,
a truncated form of p85a containing residues 1–571 fused to
a fragment of Eph (p65) was identified in an X-ray-irradiated
mouse lymphoma model (Borlado et al., 2000; Chan et al.,
2002; Jimenez et al., 1998). However, this mutation has so far
not been found in human cancers. Although, a p85a truncation
mutant was described in a human lymphoma cell line (Jucker
et al., 2002), its relevance in oncogenesis is not clear (Horn
et al., 2008). A low prevalence of p85a mutation in breast
(Wood et al., 2007), colon (Philp et al., 2001), and ovarian (Philp
et al., 2001) tumors has been reported, but the functional role of
these mutations in tumorigenesis is not known. Recently,
frequent occurrence of p85a mutations in glioblastoma was
reported (Parsons et al., 2008; TCGA, 2008). However, the ability
and role of thesemutations in promoting oncogenesis remains to
be studied.
In this study we have systematically sequenced a large
number of tumors and found mutations in p85a that uncouple
its p110-inhibitory effects from the stabilization activity, leading
to p110-mediated survival signaling and oncogenesis.
RESULTS
Identification of PI3K Regulatory Subunit Mutations
We sequenced coding exons and an 50 bp region flanking the
exons of PIK3R1, PIK3R2, PIK3R3, PIK3R4, and PIK3R5 regula-
tory subunits of PI3K in primary human cancers. A total of 672
human primary tumor samples consisting of 213 non-small-cell
lung, 108 colorectal, 62 breast, 87 renal cell, 46 ovary, 40 skin
(melanomas), 37 gastric, 21 small-cell lung, 16 esophageal, 13
bladder, 12 chronic lymphocytic leukemia, 11 hepatocellular,
and 6 pancreatic cancers were analyzed (see Table S1 available
online). We found that PIK3R1, which codes for p85a, was
mutated in 9 of 108 colorectal (8%), 1 of 62 breast (2%), and 1
of 6 pancreatic (17%) tumor samples (Figure 1, Figure S1, and
Tables S1 and S2). All the mutations were confirmed to be464 Cancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc.somatic by their presence in the original tumor DNA and absence
in the matched adjacent normal tissue through additional
sequencing or mass spectrometric analysis (Figures S1 and
S2). A majority of the mutations identified were amino acid
substitutions that clustered in the iSH2 domain. Interestingly,
one of the mutated residues, N564, was within hydrogen
bonding distance of p110a C2 domain residue N345 (Huang
et al., 2007; Figures 1A and 1C). Substitutions at residue N345
of p110a are oncogenic (Gymnopoulos et al., 2007), probably
due to destabilization of iSH2-C2 inhibitory interactions. There-
fore, it is likely that the p85a N564D mutation mimics the effect
of N345 substitutions in p110a. Interestingly, both N564 and an
adjacent residue, D560 of p85a, which is also within hydrogen
bonding distance of N345 of p110a, were recently reported to
be mutated in glioblastoma (TCGA, 2008). Though the potential
effect of these substitutions on relieving the inhibitory contacts
have been proposed (TCGA, 2008), the actual functional con-
sequence of the mutation and its role in oncogenesis have not
been explored. The regulatory p85a subunit, besides regulating
p110a, also regulates p110b and p110d (Engelman et al., 2006;
Vanhaesebroeck et al., 2005). A similar set of regulatory
contacts, involving residue N344 in p110b and residue N334
p110d, analogous to p110a residue N345, and p85a iSH2 resi-
dues N564 and D560, has been previously proposed (Amzel
et al., 2008). Our modeling of the C2 domain of p110b and
p110d supports these regulatory interactions (Figure 1C), sug-
gesting that the p85a mutations may lead to general activation
of all class IA catalytic subunits.
In addition to mutations that clustered in iSH2, we identified
mutations in the cSH2 domain, specifically a mutation in residue
R649, which is part of the conserved FLVERS motif required for
phosphotyrosine engagement (Hoedemaeker et al., 1999). The
R649 mutation is likely to alter the activity of the protein, given
that analogous conserved Arg residues within SH2 domains of
other proteins are mutated in multiple human diseases (Fig-
ure S3). Mutations in the nSH2 and BCR domains and in the
spacer between those domains were also identified (Figure 1A).
It is noteworthy that the majority of the mutated residues identi-
fied within nSH2, iSH2, and cSH2 were conserved across the
p85 family (Figure 1 and Figure S4). Meta-analysis of mutations
in p85a (Jimenez et al., 1998; Jucker et al., 2002; Parsons
et al., 2008; Philp et al., 2001; TCGA, 2008; Wood et al., 2007)
revealed several recurrent mutation sites that include R348,
G376, L380, K459, D560, N564, and R574. Interestingly, these
mutated sites are conserved across the three closely related
p85 family members (p85a/p55a/p50a, p85b, and p55g), sug-
gesting that these mutations are likely to have a functional role
in oncogenesis. We also detected mutations in PIK3R2 (p85b)
and two additional regulatory subunits, PIK3R4 (p150) and
PIK3R5 (p101), albeit at much lower frequencies (Figure S5
and Tables S2 and S3).
In addition to sequencing PI3K regulatory subunit genes, we
tested the tumor samples for somatic mutations in PIK3CA,
KRAS, and PTEN. In colon tumor bearing p85a mutations,
we rarely found KRAS or PTEN mutations. However, 45% of
p85a mutant colon tumor samples had PIK3CA mutations, sug-
gesting that the p110a and p85amutations are not always mutu-
ally exclusive in this tumor type (Figure 1D, Figure S6, and Tables
S2 and S3). Unlike in colon cancer, published PIK3R1 mutation
Cancer Cell
p85a Somatic Mutations Promote TumorigenesisFigure 1. p85a Mutations in Human Cancer
(A) Cartoon depicting the p85a somatic mutations. Horizontal bar belowmutated residues indicates conserved residues across the p85 family members (R1–R3).
Black and orange vertical bars indicate previously identified p85a mutations (Jimenez et al., 1998; Jucker et al., 2002; Parsons et al., 2008; Philp et al., 2001;
TCGA, 2008; Wood et al., 2007). Orange bars signify hotspots, with the bar height drawn proportional to number of times the residue/region has been altered.
1, TCGA, 2008; 2, Parsons et al., 2008; 3, Jimenez et al., 1998.
(B) p85a somatic mutations modeled on a recent crystal structure (PDB code 2RD0) of p85a iSH2 domain in complex with p110a (Huang et al., 2007). Blue
patches on the surface of p110a represent regions that are <3.5A˚ from p85a iSH2.
(C) The p85a residues, N564 andD560, within hydrogen bonding distance of N345 of p110a (Huang et al., 2008; TCGA, 2008) located in theC2 domain are shown.
Models of p110b (yellow) and p110d (purple) C2 domains superimposed on p110aC2 domain (cyan) illustrates the proximity of conserved residue N344 of p110b
and N334 of p110d (corresponding to N345 of p110a) and p85a iSH2 residues D560 and N564.
(D) Mutation map of tumors carrying changes in one or more of the genes studied. Each column corresponds to a tumor sample. Pc, pancreatic cancer.Cancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc. 465
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p85a Somatic Mutations Promote TumorigenesisFigure 2. p85a Mutants Interact with p110a and Stabilize p110a
(A–D) HA-tagged p85amutants and wild-type p85a that carry an intact p110a interaction domain immunoprecipitate p110a from Cos7 cells transfected with the
constructs indicated in the panels. Expression of all the transfected constructs was confirmed in the lysates as shown below in each of the panels. The dominant-
negative p85D and empty vector-transfected cells served as controls.
(E) p85a mutants that contain an intact p110a binding domain when transiently expressed in pan-p85 null MEFs stabilize p110a levels.data shows that it is mutually exclusive with PIK3CAmutations in
glioblastoma (Parsons et al., 2008; TCGA, 2008), although the
frequency of PIK3CA mutations in glioblastoma is known to be
low (Hartmann et al., 2005) compared with colon cancers (Bader
et al., 2005; Table S2). PTEN mutations generally are rare in
colon cancers (Wang et al., 1998), but co-occurred with
PIK3R1 mutations in two of our samples (Table S3). In a similar
analysis of the published glioblastoma data, we found only one
of the PIK3R1 mutations to co-occur with PTEN mutation, even
though PTEN mutations are quite frequent in glioblastomas
(Parsons et al., 2008; TCGA, 2008; Yin and Shen, 2008).
p85a Mutants Interact with and Stabilize p110a
To understand the function of p85amutations, we tested them for
their ability to interact with p110a. In coimmunoprecipitation
experiments using COS-7 cells, we found that overexpressed
HA-tagged p85a wild-type and point mutants that contained an
intact p110-binding domain (Dhand et al., 1994; Huang et al.,
2007; Miled et al., 2007) were able to interact with p110a
(Figure 2A). Similarly, p85a mutants with a short insertion
(H669insLKH), a short deletion (QYL579delL), or a premature
stop (R642*) were all able to interact with p110a, as demonstrated
by thepresenceofp110a in the immunoprecipitatedp85a (Figures466 Cancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc.2B and 2D). Additionally, the C2-iSH2 interaction region mutants
D560Y and D560Y_N564D were able to interact with p110a
(Figure 2C). As previously described, a truncated p85 mutant,
Q572*, was also able to interact with p110a (Shekar et al., 2005).
However, p85a mutants that lacked the p110a binding region,
namely R162*, L380fs, R348*, and a dominant-negative mutant,
p85D (Dhandetal., 1994),all failed to interactwithp110a (Figure2).
As expected, the mock and vector control lanes in the assay did
not immunoprecipitate HA-p85a or p110a, confirming the speci-
ficity of the p85a-p110a interactions observed.
Given that most of the p85a mutants still could interact with
p110a, we next tested their ability to stabilize p110a protein
levels in immortalized pan-p85 null MEFs. It was previously
shown that the endogenous levels of p110a in the pan-p85 null
background are significantly reduced but can be restored by
reconstituting these cells with wild-type p85 (Brachmann et al.,
2005). We focused primarily on testing p85a iSH2 domain
mutants for their ability to stabilize p110a, given that the majority
of the mutations identified clustered within this domain. As with
wild-type p85a, all of the p85a mutants that contained an intact
p110a-binding domain stabilized p110a (Figure 2E). Consistent
with their inability to bind p110a, L380fs and the dominant-nega-
tive p85D did not stabilize p110a (Figure 2E).
Cancer Cell
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and p110d
(A and B) Indicated HA-tagged p85a mutants and
wild-type p85a cotransfected with myc-p110b (A)-
or myc-p110d (B)-immunoprecipitated p110b (A)
or p110d (B). Expression of all the transfected
constructs was confirmed in the lysates. The
dominant-negative p85D and empty vector-trans-
fected cells served as controls.p85aMutants Interact with p110b and p110d
The p85a regulatory subunit associates with and regulates all
class IA PI3K members including p110b and p110d (Chantry
et al., 1997; Engelman et al., 2006; Hu et al., 1993; Vanhaese-
broeck et al., 2005). Hence, we tested the ability of myc-tagged
p110b or p110d to interact with a subset of p85a mutants pre-
dicted to destabilize the C2-iSH2 interactions (Figure 1C). We
found that overexpressed HA-tagged p85a wild-type, D560Y,
N564D, D560Y_N564D, QYL579delL, and Q572*, all of which
contained an intact p110-binding domain (Dhand et al., 1994;
Huang et al., 2007; Miled et al., 2007), were able to interact
with both p110b and p110d (Figures 3A and 3B). However, as
expected, dominant-negative mutant p85D (Dhand et al., 1994)
and the mock and vector control lanes did not immunoprecipi-
tate p110b or p110d (Figures 3A and 3B), confirming the speci-
ficity of the p85-p110b/d interactions observed.
Mutant p85a/p110 Class IA PI3K Holoenzymes AreMore
Active
Having established that the p85a mutants can interact with
p110a, p110b, and p110d, we tested if the mutations altered
the ability of p85a to suppress the activity of the catalytic
subunit. In order to study this, we expressed, purified, and tested
heterodimeric p85a/p110 class IA PI3K wild-type or mutant
enzymes for their lipid kinase activity. The mutants tested were
selected based on the stabilization activity data (Figure 2E), the
transient cell survival analysis (Figure S7), the structural rele-
vance of p85a N564 (Huang et al., 2007) mutation, and the prox-
imity of QYL579delL mutation to the oncogenic murine Q572*
mutation (Jimenez et al., 1998).
In testing the PI3K activity of purified recombinant iSH2
domain mutant p85a/p110a holoenzyme, we found that relative
to the wild-type p85a/p110a, the N564D mutant and QYL579
delL iSH2 p85 mutant had 1.7- to 2.0-fold increase in activity
asmeasured by an in vitro phosphatidylinositol (PI) phosphoryla-
tion assay (Knight et al., 2007; Figures 4A and 4B). As expected,
themurine Q572* mutant (Chan et al., 2002; Jimenez et al., 1998;
Shekar et al., 2005) showed increased kinase activity compared
with the wild-type. We further tested the p85a mutants in an
alternate assay using nSHi proteins composed of a minimal
p85a wild-type fragment that spans the nSH2 and iSH2 (amino
acids 320–600) domains (Shekar et al., 2005). This minimal
nSHi wild-type p85a protein is known to inhibit overexpressed
p110a activity in cell lysates (Shekar et al., 2005). Consistent
with the holoenzyme activity observed, mutant nSHi proteins
showed decreased p110a activity inhibition (Figure S8). DespiteCthe increased PI3K activity, the mutant p85a/p110a holoen-
zymes were effectively inhibited by a p110a/d inhibitor (Folkes
et al., 2007).
Having established the elevated lipid kinase activity of mutant
p85a/p110a holoenzyme, we next measured the PI3K activity of
purified recombinant iSH2 domain wild-type or mutant p85a/
p110b and p85a/p110d holoenzymes. We found that relative to
the wild-type p85a/p110b, the N564D and QYL579delL iSH2
p85/p110b mutant enzymes had 1.6- to 1.8-fold increase in
activity as measured by an in vitro PI phosphorylation assay
(Knight et al., 2007; Figures 4C and 4D). Similarly, relative to
wild-type p85a/p110d holoenzyme, the N564D mutant and
QYL579 delL iSH2 p85/p110dmutant enzymes showed elevated
lipid kinase activity (1.2-fold) although the increase in lipid
kinase activity was low compared to p85a/p110a or p85a/
p110b mutant holoenzymes (Figures 4E and 4F). Consistent
with the impaired inhibition by the p85a mutants across all the
class IA catalytic subunits, the murine mutant Q572* p85a/
p110b and p85a/p110d enzymes also showed increased kinase
activity compared with the wild-type enzyme (Figures 4A–4F).
Similar to mutant p85a/p110a enzymes, the lipid kinase activity
of mutant p85a/p110b or p85a/p110d was effectively inhibited
by a p110b (Jackson et al., 2005) or p110a/d inhibitor (Folkes
et al., 2007), respectively (Figures 4C–4F and Figure S9), indi-
cating that pan-p110 class IA inhibitors are likely to be effica-
cious in patients with p85a mutations.
p85aMutants Promote AKT Activation and Cell Survival
In order to further understand the functional relevance of the
p85a mutations we investigated their ability to render the IL-3-
dependent murine BaF3 cells growth factor independently by
stably expressing the iSH2 mutants either alone or in combina-
tion with wild-type p110a, p110b, or p110d. We additionally
tested a glioblastoma iSH2 domain mutant, D560Y, and a
synthetic-iSH2 double mutant, D560Y_N564D, for their ability
to promote IL-3-independent growth of BaF3 cells. Stable
expression of the HA-tagged p85a mutants either alone or
together with myc-tagged p110a, p110b, or p110d in the BaF3
cells was confirmed by western blotting (Figures 5A–5D). Unlike
wild-type p85a, all of the p85a mutants tested promoted IL3-
independent BaF3 cell survival either on their own or in combina-
tion with p110a, p110b, or p110d (Figures 5A–5H). This survival
benefit was blocked by a p110a/d or a p110b (TGX-221) inhibitor
(Folkes et al., 2007; Jackson et al., 2005), confirming the require-
ment of p110 activity for the observed p85a mutant-mediated
survival effect (Figures 5E–5H). Given that elevated class IAancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc. 467
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stream, prosurvival kinase AKT (Engelman et al., 2006), we
tested the stable BaF3 cells expressing the mutant p85a for
the phospho-AKT (pAKT) levels following IL3 withdrawal. Con-
sistent with the ability of the mutants to promote cell survival,
cells that expressed p85a mutants had increased pAKT when
compared to cells expressing wild-type p85a (Figures 5A–5D
and Figures S10A–S10D).
In addition to cell survival, the p85a mutants D560Y, N564D,
N564D_D560Y, and QYL579delL also promoted anchorage-
independent growth of BaF3 cells in a class IA PI3K activity-
dependent manner that was blocked by PI3K inhibitors (Figures
6A–6F). To further confirm that the p85 iSH2 C2 contact mutants
were unable to inhibit p110 activity, we stably reconstituted the
expression of the p85a mutants in pan-p85 null MEFs (Brach-
mann et al., 2005) using a retroviral vector. As observed in our
transient reconstitution studies (Figure 2E), all the p85amutants
stabilized the expression of endogenous p110a similar to wild-
type p85a (Figure 6G). In addition to stabilizing p110a, wild-
type and mutant p85a expression also stabilized p110b and
p110d (Figure 6G). Also, MEFs expressing D560Y, N564D,
D560Y_N564D, QYL579delL, and the Q572* murine mutant
showed an increase in proliferation when compared to MEFs
Figure 4. p85a Mutants Are Impaired in
Regulating Class IA PI3K Activity
(A, C, and E) Dot blots show the amount of phos-
phorylated lipid generated by each of the tested
heterodimeric enzymes in triplicates.
(B, D, and F) Mean ± SEM of the amount of phos-
phorylated lipid generated in (A), (C), and (E) by
each of the enzyme complexes in arbitrary units.
Elevated PI3K activity is effectively inhibited by
a p110a/d (B and F) or p110b (TGX-221; D) inhib-
itor (Folkes et al., 2007; Jackson et al., 2005).
Mean ± SEM percentage of control (p85a-WT)
activity is shown. *p < 0.05, **p < 0.01, and
***p < 0.001.
expressing wild-type p85a or empty
vector (Figure 6H). Consistent with this,
MEFs expressing mutant p85a showed
a higher basal level of pAKT/AKT (Fig-
ure 6H and Figure S10E). Taken together,
these data indicate that the iSH2 p85a
mutations do not affect p85a-mediated
p110 stabilization, but impair p85a’s
ability to negatively regulate class IA
PI3Ks, leading to AKT-mediated cell
survival and proliferation.
p85a Mutants Promote
Oncogenesis In Vivo
BaF3 cells that stably express oncogenic
p110a mutants promote leukemia and
reduced survival when transplanted into
mice (Horn et al., 2008). Since the p85a
mutants promote BaF3 cell survival,
anchorage-independent growth, and pro-
liferation in vitro in a p110-dependent manner (Figures 5 and 6),
we tested p85a/p110a eGFP/dsRed-tagged BaF3 cells for
induction of leukemia-like disease in mice. Mice transplanted
with BaF3 cells expressing mutant p85a subunit together with
wild-type p110a showed a median survival of 30 to 40 days (Fig-
ure 7A). With the exception of one animal that received cells
expressing p110a alone, all mice that received BaF3 cells ex-
pressing either wild-type p85a or coexpressing wild-type p85a
and p110a or that had been transduced with empty vector
were still alive at the end of the 55 day study period. Necropsies
were conducted at 30 days on an additional cohort of three mice
per treatment to follow disease progression. Bone marrow,
spleen, and liver samples from these animals were reviewed
for any pathological abnormalities. As the BaF3 cells were
tagged with eGFP and/or dsRed, we examined isolated bone
marrow for infiltrating cells by fluorescence-activated cell sorting
(FACS). The bone marrow from mice transplanted with cells
expressing mutant p85a showed a significant proportion of infil-
trating eGFP/dsRed-positive cells compared with bone marrow
frommice receiving wild-type p85a or empty vector control cells
(Figures 7B and 7C). Consistent with the FACS data, in mice
receiving cells expressing mutant p85a, histological evaluation
of spleen and liver stained with hematoxylin and eosin (H&E)468 Cancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc.
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p85a Somatic Mutations Promote TumorigenesisFigure 5. p85a Mutants Promote p110-Dependent Cell Survival and AKT Signaling
(A–H) Stable expression p85amutants alone (A and E) or together with p110a (B and F), p110b (C and G), or p110d (D and H) promote IL3-independent survival of
BaF3 cells (E–H) and elevated pAKT (A–D) levels. The cell survival effects (E–H) of p85amutants are inhibited by a p110a/d or p110b (TGX-221) inhibitor (Folkes
et al., 2007; Jackson et al., 2005). Data shown in (E–H) aremean ± SEMof at least three independent experiments withmultiple replicates. *p < 0.05 and **p < 0.01.showed significant infiltration of blasts (Figure 7D). However,
in mice receiving cells expressing wild-type p85a or empty
vector-transduced cells, there was little or no evidence of blast
infiltration (Figure 7D). Mice carrying the mutant p85a/p110a-
expressing cells also showed increased spleen and liver weight,
which is consistent with an infiltration of cells into the liver and
spleen (Table 1). These results demonstrate the in vivo leukemo-
genic potential conferred by the p85amutants on hematopoietic
cells.
DISCUSSION
Mutations in the p110a catalytic subunit of PI3K are common in
colon cancers (Samuels et al., 2004). In this study, we have iden-
tified the occurrence of frequent p85a regulatory subunit muta-
tions in colon cancer. The p85a mutants were unable to nega-
tively regulate p110a, p110b, and p110d activity, despite
retaining their ability to stabilize them. Of particular interest is
a group of mutations in p85a at the interface between p85a-
iSH2 and C2 domain of p110a described in a recent crystal
structure (Huang et al., 2007; TCGA, 2008). The mutated resi-
dues in p85a N564 and D560 are within hydrogen bond distance
of residue N345 in p110a, which, when mutated, renders p110a
oncogenic (Gymnopoulos et al., 2007). These iSH2 mutationsCmimic the effects of substitutions at N345 C2 domain of p110a
in that they promote elevated p110a activity and therefore cell
survival. In vivo, thesemutants were capable of promoting onco-
genesis, confirming the relevance of these mutants in colon
cancer and glioblastoma. In addition, mutation at Q579 within
the iSH2 also confers properties similar to mutations at N564
or D560, although the structural implication of this mutation
remains to be understood. Taken together with the previously
described murine Q572* mutant (Jimenez et al., 1998), these
findings suggest that this region of iSH2 is a potential hotspot
for the accumulation of p85a mutations that confer a cellular
growth advantage.
Though oncogenic mutations in p110a are common, such
mutations in other class IA PI3Ks, p110b and p110d, are not
common (Bader et al., 2005; Samuels et al., 2004). The p85a
subunit, besides interacting and regulating p110a, can heterodi-
merize with p110b and p110d and regulate their activity (Chantry
et al., 1997; Engelman et al., 2006; Hu et al., 1993; Vanhaese-
broeck et al., 2005). Consistent with this, as observed with
p110a, we found that the p85a mutants were able to interact
and stabilize both p110b and p110d. However, the p85amutants
were impaired in the ability to negatively regulate p110b and
p110d activity. This is supported by our structural modeling
and the proposal in a recent review (Amzel et al., 2008), whichancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc. 469
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(A–F) A representative image showing anchorage-independent growth (A–C) and number of colonies formed in the absence or presence of PI3K inhibitors (D–F)
by BaF3 cells stably expressing p85a mutants together with p110a (A), p110b (B), or p110d (C).
(G and H) Pan-p85 null MEFs stably reconstituted with p85a mutants show stabilization of p110a, p110b, and p110d (G), elevated pAKT (G), and increased cell
proliferation (H). Data shown (D–F and H) are mean ± SEM. *p < 0.05 and **p < 0.01.suggest the presence of a conserved set of regulatory interac-
tions between p110-C2 iSH2-p85a across all three class IA
PI3Ks. Our findings indicated that mutations in p85a could serve
as a global mechanism for deregulation of class IA PI3K activity
in cancers. This is consistent with the emerging role of p110b and
p110d in cancer (Kang et al., 2006; Zhao and Vogt, 2008).
Besides deregulation of class IA PI3K activity by the p85a
mutants, the impact of the p85amutations on p110-independent
p85a functions (Garcia et al., 2006; Taniguchi et al., 2006), the
role of the additional p85amutants, and the activity of co-occur-
ring p85a/p110a double mutant enzymes may all contribute to
pathogenesis and remain to be explored. In gliomas, where
p110a mutations are not common (Bader et al., 2005), our data
on the function of p85a mutations indicate that such mutants
may play a major role for PI3K pathway activation, in addition
to PTEN inactivation (Parsons et al., 2008; TCGA, 2008; Yin
and Shen, 2008).
Taken together, our data show that PIK3R1 is a frequently
mutated, functionally relevant colon cancer gene. Consistent470 Cancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc.with our findings, a recent forward genetic screen in mouse for
colon cancer genes identified PIK3R1 as a site of transposon
insertion in several independent lines (Starr et al., 2009). With
the identification of PIK3R1 mutations and the establishment of
their functional relevance, it is very likely that the p85 mutations
when used as biomarkers should allow the detection of p110-
dependent p85 mutant tumors that are very likely to respond
to treatment with inhibitors that target PI3Ks or their downstream
effectors, such as AKT.
EXPERIMENTAL PROCEDURES
Tumor DNA, Mutation, and Genomic Amplification
Primary human tumor samples with appropriate IRB approval and patient
informed consent were obtained from commercial sources (Table S1). The
human tissue samples used in the study were de-identified (double-coded)
prior to their use and hence the study using these samples is not considered
human subject research under the US Department of Human and Health
Services regulations and related guidance (45 CFR, Part 46). Tumor content
in all the tumors used was confirmed to be >70% by pathology review. Tumor
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p85a Somatic Mutations Promote TumorigenesisFigure 7. p85a Mutants Lead to Reduced Overall Survival
(A) Kaplan-Meier survival curves for cohorts of mice implantedwith p85amutant expressing BaF3 cells compared to vector control cells or p85awild-type cells or
p110a cells alone or p85a /p110a cells showed a significant reduction in overall survival (n = 10 for each arm; Log-rank test, p < 0.0001).
(B) Flow cytometric analysis of total bone marrow isolated from mice receiving GFP- and/or dsRed-tagged BaF3 cells expressing the various p85a mutants.
(C) Mean number of GFP- and/or dsRed-positive cells in the bone marrow of mice (n = 3) that received BaF3 cells expressing p85amutants. Values are mean ±
SEM.
(D) Representative H&E-stained liver (top) and spleen (bottom) sections from the samemice analyzed in (B). Arrows indicate tumor cells infiltrating the liver. R, red
pulp; W, lymphoid follicles of white pulp. In unmarked spleen section, there is a loss of red/white pulp architecture due to disruption by infiltrating tumor cells.
Scale bar corresponds to 100 mm.DNA was extracted using QIAGEN Tissue easy kit (QIAGEN). All coding
exons of PIK3R1-R5, PIK3CA, KRAS, and PTEN were amplified using
primers listed in Table S4 and sequenced using 3730xl ABI sequencer
(Applied Biosystems). The PCR products were generated using two pairs
of primers, an outer pair and an inner pair, to increase the specificity (Table
S4), using standard PCR conditions. The sequencing data was analyzed for
presence of protein variants not present in the dbSNP database using
Mutation Surveyor (Softgenetics) and additional automated sequence align-
ment programs. The putative variants identified were confirmed for their
presence by DNA sequencing or mass spectrometry analysis (Sequenom)
of the original tumor DNA followed by confirmation of its absence in the
adjacent matched normal DNA by a similar process applied to the tumor
DNA (Figures S1 and S2).
The C2 homology models we generated by ESyPred3D (Lambert et al.,
2002) server, using C2 domain sequences and the crystal structure of P110a
(PDB: 2RD0) as a template. The initial homology model was then improvedCby manual adjustment and geometric optimization with COOT (Emsley and
Cowtan, 2004).
Genomic DNA from tumor samples as annotated in Table S1 was analyzed
using an Affymetrix GeneChip mapping 100,000 arrays (Affymetrix) as per the
manufacturer’s instructions. Copy number data were generated for each array
by using the Affymetrix Chromosome Copy Number Tool (CNAT) v.2.0 (Huang
et al., 2004) and/or dChipSNP (Lin et al., 2004).
Cell Lines
The IL-3-dependent mouse pre-B cell line BaF3 and Cos7 cells were
purchased from American Type Culture Collection. BaF3 cells were main-
tained in RPMI 1640 supplemented with 10% (v/v) fetal bovine serum (Thermo
Fisher Scientific), 2 mM L-glutamine, 100 U/ml penicillin, 100 mg/ml strepto-
mycin (complete RPMI), and 2 ng/ml mouse IL-3. The p85 a and b knockout
mouse embryonic fibroblasts (Pan-p85 MEFs) were obtained form L.C. Cant-
ley’s laboratory (Harvard Medical School) and maintained in DMEMancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Inc. 471
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p85a Somatic Mutations Promote Tumorigenesissupplemented with 15% (v/v) fetal bovine serum, while Cos7 cells were main-
tained in DMEM supplemented with 10% (v/v) fetal bovine serum, 2 mM
L-glutamine, 100 U/ml penicillin, and 100 mg/ml streptomycin. Phoenix (Orbi-
gen) cells were maintained in DMEM supplemented with 10% FBS. Spodop-
tera frugiperda (Sf9) insect cells (Vaughn et al., 1977) were grown in ESF 921
serum-free medium (Expression systems LLC).
Plasmids and Antibodies
Eukaryotic expression plasmid pRK5E, driving the expression of HA- p85a
mutants, untagged p110a, N-myc-tagged p110a, N-myc-tagged p110b, and
N-myc-tagged p110dwere constructed using standard PCR and cloning strat-
egies. pRetro-IRESdsRed (Clontech) or a version of this retroviral vector with
GFP in place of dsRed was used to stably express HA-p85a, N-myc-p110a
(Yu et al., 1998), N-myc-p110b, and N-myc-p110d. Recombinant baculovirus
expressing N-His6-p110a, N-His6-p110b, N-His6-p110d, and untagged p85a
driven by the polyhedrin promoter were prepared according to the manufac-
turer’s recommendations using the Bac-to-Bac Expression System (Invitro-
gen). GST fusion constructs expressing p85 nSHi made of amino acids
320–600 (Shekar et al., 2005) was made in pGEX6p-2 (GE Healthcare).
Antibodies that recognize pAKT (Ser473) and AKT (Cell Signaling Tech-
nology), p110b (Cell Signaling Technology), p110a and p110d (Epitomics),
c-Myc (Genentech Inc.), and b-actin and Flag M2 (Sigma-Aldrich) were used
in the study. Horseradish peroxidase (HRP)-conjugated HA antibody (Roche
Molecular Biochemicals) and HRP-conjugated secondary antibodies (Pierce
Biotechnology) were used in western blots. Anti-HA rat monoclonal (clone
3F10)-coupled affinity matrix (Roche Diagnostics) and c-Myc tag IP applica-
tion kit (Thermo Fisher Scientific) were used for immunoprecipitation studies.
Recombinant Proteins
To generate recombinant heterodimeric PI3K enzyme, 1 liter of 2 3 106 Sf-9
cells/ml was co-infected with either p110a or p110b or p110d and p85a
expressing baculoviruses at an multiplicity of infection of 0.5 each. Cell pellets
were harvested at 72 hr after infection and lysed in lysis buffer A [50 mM Tris
HCl (pH 8.0), 0.3 M NaCl, 20 mM Imidazole, 1 mM TCEP, and protease inhib-
itors]. The cell lysate was clarified by spinning at 35,0003 g for 1 hr at 4C. The
clarified supernatant was loaded over a Ni-NTA Superflow (QIAGEN) column
pre-equilibrated with lysis buffer A. The His6P110a/p85a complex was eluted
using immidazole gradient (20 mM to 250 mM) made using buffer B [20 mM
Tris HCl (pH 8.0), 0.3 M NaCl, and 0.25 mM TCEP]. The purified His6P110/
p85a was further purified on a Superdex 200 size exclusion column pre-equil-
ibrated with 25mMTris (pH 7.5), 150mMNaCl, 0.25mMTCEP, and 10% glyc-
erol. Purified proteins were serially diluted and resolved on SDS-containing
PAGE for concentration assessment (Figure S11).
BL-21 E. coli cells transformedwith the appropriate pGEX6p-2 nSHi expres-
sion construct were induced to express GST fusion proteins as per the manu-
facturer’s recommendations. Cell pellet from 1 liter culture was lysed in lysis
buffer C (PBS, 2 m MDTT, and protease inhibitors), microfluidized, and centri-
Table 1. Characterization of BAF3-p85a Implanted Mice
Weights
Transplanted Cells Body Spleen Liver
Empty vector 20.9 ± 0.7 0.44 ± 0.11 1.17 ± 0.24
P85a-WT 20.3 ± 0.4 0.11 ± 0.01 1.16 ± 0.01
P110a-WT 22.1 ± 0.9 0.21 ± 0.05 1.15 ± 0.01
P85a-WT + p110a-WT 20.3 ± 0.4 0.11 ± 0.01 1.37 ± 0.01
P85a-D560Y + p110a-WT 20.9 ± 0.8 1.18 ± 0.15** 2.87 ± 0.30**
P85a-N564D + p110a-WT 20.9 ± 0.5 0.97 ± 0.14** 2.88 ± 0.49**
P85a D560Y_N564D +
p110a-WT
21.3 ± 0.3 0.87 ± 0.03** 2.51 ± 0.32**
Balb/C mice received 2 3 106 /BaF3 cells stably expressing p110a wild-
type (p110a-WT) and p85a wild-type (p85a-WT) or mutants (n = 3) or the
vector (n = 3) by tail-vein injection. Allografted mice were sacrificed
5 weeks after transplantations and tissues were collected and analyzed.
**p < 0.01 versus p85a-WT + p110a-WT.472 Cancer Cell 16, 463–474, December 8, 2009 ª2009 Elsevier Incfuged at 35,000 3 g for 1 hr at 4C. Clarified lysate was loaded over a GST-
Sepharose 4 fast flow (GEHealthcare) column pre-equilibrated with lysis buffer
C. BoundGST-p85 nSHi was eluted using buffer B [50mMTris (pH 8.0), 10mM
NaCl, 1mMEDTA, 2mMDTT, and 10mMGSH]. Eluted proteins were dialyzed
into bufferD [20mMTris (pH8), 150mMNaCl, 1mMEDTA, and0.25mMTCEP]
and incubated with PreScission protease (GE Healthcare) at 4C overnight
to remove the GST tag. The untagged p85 nSHi in the dialyzed and digested
material was recovered by passing it over a GST-Sepharose column. The
nSHi protein was further purified by size exclusion on a Superdex 200 column.
Generation of Stable Cell Lines
Retroviral constructs expressing HA-p85-dsRed and/or myc-p110-GFP were
transfected into Phoenix amphoteric cells using Lipofectamine (Invitrogen).
The resulting virus was then transduced into BaF3 cells and pan-p85 null
MEFs. The top 10% of the infected cells based on the expression of retroviral
IRES-driven dsRed and/or GFP were sterile sorted by flow cytometry and
characterized for expression of proteins by western blot. Pools of these cells
were then used in further studies.
Immunoprecipitation and Western Blot
Cos-7 (2.5 3 105) or pan-p85 null MEFs (10 3 106) cells were transfected or
nucleofected with appropriate constructs expressing HA-p85 and/or p110
wild-type DNA using Fugene 6 (Roche diagnostics) or nucleofection kit 1
(Amaxa Inc.) following the manufacturer’s protocol. At 48 hr posttransfec-
tion/nucleofection, cells were washed with PBS and lysed in a lysis buffer I
[50 mM Tris HCl (pH 7.5), 150 mM NaCl, 1 mM EDTA, and 1% Triton X-100).
The clarified lysates were incubated for 2 hr at 4C with anti-HA antibody
coupled beads. The HA beads were then spun down at 500 3 g for 2 min
and washed thrice using the lysis buffer I. The immunoprecipitated proteins
remaining on the beads were boiled in SDS-PAGE loading buffer, resolved
on a 4%–20% SDS-PAGE (Invitrogen), and transferred onto a nitrocellulose
membrane. Immunoprecipitated proteins or proteins from lysates were
detected using appropriate primary, HRP-conjugated secondary antibody,
and chemiluminescence Super signal West Dura chemiluminescence detec-
tion substrate (Thermo Fisher Scientific).
Survival and Proliferation Assay
For the initial characterization of the p85a mutants, 2 3 106 BaF3 cells were
nucleofected with appropriate pRK5Ewild-type ormutant constructs express-
ing HA-p85a and/or myc-p110a DNA using nucleofection kit V (Amaxa Inc.).
After a 3 hr recovery period in media without IL-3 following nucleofection cells
were plated in 33 96 well plates in triplicates and monitored for survival. Simi-
larly, BaF3 cells stably expressing the wild-type and mutant p85a alone or
together with myc-p110a, myc-p110b, or myc-p110d were washed twice in
PBS and plated in 3 3 96 well plates in replicates of twelve in complete
RPMI medium without IL3. 500 nM of the p110 small molecule inhibitor
PI3Ki-A/D (Folkes et al., 2007) or TGX-221 (Jackson et al., 2005) in 0.1%
DMSO was used to test the effects of p110 inhibition where relevant, as
depicted in the figures. Viable cells at 0, 24, 48, 96, and 120 hrwere determined
using Cell Titer-Glo luminescence cell viability kit (Promega Corp.) and
Synergy 2 (Biotek Instrument) luminescence plate reader. All the cell number
values were normalized against 0 hr values. Normalized vector control cell
value was used to calculate the relative survival of the various mutant p85a
either alone or in combination with class IA PI3Ks. In order to assess prolifer-
ation of pan-p85 null MEFs stably expressing p85awild-type or mutants, 5000
cells in triplicates were plated in media with 15% serum and allowed to prolif-
erate for 5 days. Cell numbers were measure at day 0 and day 5 using the lumi-
nescence cell viability kit. Data was expressed as mean ± SEM of fold change
over vector or p85wild-type. Mean and statistical significancewas determined
using GraphPad V software (GraphPad).
In Vitro PI3K Activity Assay
Purified PI3K heterodimeric enzyme was quantified on a gel to estimate the
concentration of p85a along with either p110a, p110b, or p110d (Figure S11).
For each of the p110/p85a purified enzyme combination, 30 ng of the purified
protein was tested for PI3K activity as described recently (Knight et al., 2007).
Briefly, 30 ng of each of the purified enzyme was incubated for 30 min at 25C
with PI and 2 mCi [g-32P] ATP (PerkinElmer) in 25 ml of kinase reaction buffer.
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with or without 500 nM PI3KiA/D or TGX-221. At the end of 30 min, 4 ml of each
reaction was spotted onto a dry nitrocellulose membrane (Bio-Rad Laborato-
ries) using a multichannel pipette and was dried and washed five times with
wash solution (1 M NaCl in 1% H3PO4). After the washes the membrane was
dried and exposed to a phosphor screen for 1 hr. The exposed phosphor
screen was then scanned on a Typhoon phosphorimager (GE Healthcare).
The amount of bound radioactive lipid derived from PI phosphorylation by
the different PI3K enzymes studied was quantified using a MATLAB script
called Spot (Knight et al., 2007). Alternatively, inhibition of recombinant
p110a in baculovirus lysates by E. coli-expressed and -purified p85a nSHi
was directly measured as described previously (Shekar et al., 2005).
BaF3 Colony Formation Assay
BaF3 cells (2 3 105), stably expressing p110a, p110b, or p110d along with
p85a wild-type or mutants, was mixed with 2 ml of IL3-free Methocult (STEM-
CELL Technologies) with or without 500 nM PI3Ki-A/D or TGC-221 and plated
on to 6 well plates that were then incubated at 37C for 2 weeks. The presence
of colonies was assessed using Gel count imager (Oxford Optronix Ltd.). The
number of colonies in each plate was quantified using Gel count software
(Oxford Optronix Ltd.).
Animal Studies
BaF3 cells (2 3 106) expressing the p85a wild-type or mutants along with
p110a were implanted into 8–12 week old Balb/C nude mice by tail vein injec-
tion. A total of 13 animals per treatment were injected. Of this, ten mice were
followed for survival and three were used for necropsy at day 30 to assess
disease progression by histological analysis of spleen and liver. Bone marrow
single cell suspension obtained from these animals was also analyzed for the
presence and proportion of GFP- and/or dsRed-positive BaF3 cells by FACS
analysis. When possible, dead or moribund animals in the survival study were
dissected to confirm the cause of death. Morphological and histological anal-
yses of spleen, liver, and bonemarrowwas also done on these animals. Spleen
and liver were fixed in 10%neutral-buffered formalin, and then processed in an
automated tissue processor (TissueTek) and embedded in paraffin. Four
micrometer thick sections were stained with H&E (Sigma-Aldrich) and
analyzed histologically for presence of infiltrating tumor cells. Photographs
of histology were taken on a Nikon 80i compound microscope with a Nikon
DS-R camera. All animal studies were performed under Genentech’s Institu-
tional Animal Care and Use Committee approved protocols.
Statistical Analyses
Student’s t test (two tailed) was used for statistical analyses to compare treat-
ment groups usingGraphPad Prism5.00 (GraphPad Software). A p value <0.05
was considered statistically significant (*p < 0.05, **p < 0.01, and ***p < 0.001).
For Kaplan-Meier Method of survival analysis, log-rank statistics were used to
test for difference in survival.
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